Solta Medical to Participate in Two Upcoming Investor Conferences

Thursday, August 5, 2010 Press Release J E 4

HAYWARD, Calif., Aug. 4 Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced that Stephen J. Fanning, Chairman, President and Chief Executive Officer of Solta, will be participating in two upcoming investor conferences.

Attendance at these conferences is by invitation only.

A live audio webcast of the Company's presentation at the Canaccord Genuity conference may be accessed at the Investor Relations section of the Company's website at An archived replay will be available for 30 days following each event at

About Solta Medical, Inc.

Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry's three premier brands: Thermage(R), Fraxel(R) and Isolaz(R). Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz is the only laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. Since 2002, approximately one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to

Conference: Collins Stewart Health Care Event Date: Wednesday, August 11 Location: New York City, NY Conference: 30th Annual Canaccord Genuity Growth Conference Date: Thursday, August 12 Time: 10:00 am ET Location: Boston, MA.

SOURCE Solta Medical, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Beckman Coulter Signs Record Deal to Provide Integ...
Vanda Pharmaceuticals Reports Second Quarter 2010 ...